Therapeutic decision-making in inhibitor patients

American Journal of Hematology

Volumn 81, Issue 1, 2006, Pages 71-72

  Allen, Geoffrey ^a   Aledort, Louis ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8 INHIBITOR; DESMOPRESSIN ACETATE; FIBRIN GLUE; MICROCRYSTALLINE COLLAGEN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

BLEEDING; CONSENSUS; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; HEALTH CARE COST; HEMOPHILIA A; HEMOSTASIS; HUMAN; MEDICAL DECISION MAKING; MUCOSAL BLEEDING; PRIORITY JOURNAL; SHORT SURVEY; THROMBOSIS;

BLOOD COAGULATION FACTORS; COSTS AND COST ANALYSIS; DECISION MAKING; DRUG COMBINATIONS; FACTOR VII; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; ISOANTIBODIES; RECOMBINANT PROTEINS;

EID: 30444433618     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20474     Document Type: Short Survey

References (10)

1. Goudemand J, Tagariello G, Lopaciuk F. Cases of surgery in high-responder haemophilia patients. Haemophilia 2004;10(Suppl 2):46-49.
2. Tjønnfjord GE, Brinch L, Gedde-Dahl G, Brosstad FR. Activated prothrombin complex concentrate (FEIBA®) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 2004;10:174-178.
3. Arkin S, Blei F, Fetten J, et al. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors. Blood Coagul Fibrinolysis 2000;11:255-259.
4. Negrier C, Hay CR. The treatment of bleeding in hemophilic patients with inhibitors with recombinant factor VIIa. Semin Thromb Hemost 2000;26:407-412.
5. Bui JD, Despotis GD, Trulock EP, Patterson GA, Goodnough LT. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg 2002;124:852-854.
6. Schneiderman J, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia 2004;10:347-351.
7. Key NS, Christie B, Henderson N, Nelsestuen GL. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy. Thromb Haemost 2002;88:60-65.
8. Ehrilich HJ, Henzel MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA®): 10-year compilation of thrombotic adverse events. Haemophilia 2002;8:83-90.
9. 3rd, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004;41(Suppl 1):101-108.
10. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004;2:1700-1708.